ReviewInternational journal of molecular sciences2020
The "Janus Face" of Platelets in Cancer.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Systemic immune-inflammation index and the survival of hepatocellular carcinoma patients after transarterial chemoembolization: a meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Efficacy and safety of eltrombopag in the treatment of cancer therapy-induced thrombocytopenia: a large-scale, multicenter, retrospective study in China.Blood science (Baltimore, Md.) · 2026Article
- Platelet‑circulating tumor cell crosstalk: A pivotal target in cancer diagnosis and therapy (Review).Oncology reports · 2026Review
- Immune system, inflammatory response, and regulated cell death in breast cancer research (Review).Oncology reports · 2026Review
- Tumor-mediated remote regulation of peripheral blood platelets.Cell biology and toxicology · 2025Review
- Association of non-insulin-based insulin resistance indices, mean platelet volume and prostate cancer: a cross-sectional study.BMC cancer · 2025Article
- The tumor microenvironment: adding pieces to the puzzle.Frontiers in immunology · 2025Review
- Prognostic Value of the SII-PNI Score in Unresectable HCC Treated with Transcatheter Arterial Chemoembolization Combined with Lenvatinib and PD-1 Inhibitors.Journal of inflammation research · 2025Article
- Pre-treatment thrombocytosis and ovarian cancer survival: A meta-analysis.European journal of obstetrics & gynecology and reproductive biology: X · 2024Review
- Synthesis of Novel Nilotinib Analogues and Biological Evaluation of Their Antiplatelet Activity and Functionality towards Cancer Cell Proliferation In Vitro.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Exploring cell-derived extracellular vesicles in peripheral blood and bone marrow of B-cell acute lymphoblastic leukemia pediatric patients: proof-of-concept study.Frontiers in immunology · 2024Article
- Tumor cell-induced platelet aggregation accelerates hematogenous metastasis of malignant melanoma by triggering macrophage recruitment.Journal of experimental & clinical cancer research : CR · 2023Article
- Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment.Diagnostics (Basel, Switzerland) · 2023Article
- Platelet-Derived Microparticles and Autoimmune Diseases.International journal of molecular sciences · 2023Review
- Platelets are highly efficient and efficacious carriers for tumor-targeted nano-drug delivery.Drug delivery · 2022Article
- Pancreatic Cancer Cells Induce MicroRNA Deregulation in Platelets.International journal of molecular sciences · 2022Article
- Cancer-related stroke: Exploring personalized therapy strategies.Brain and behavior · 2022Review
- Association between c-type lectin-like receptor 2 and microsatellite instability in colorectal cancer: a cross-sectional study.BMC cancer · 2022Article
- Platelets involved tumor cell EMT during circulation: communications and interventions.Cell communication and signaling : CCS · 2022Review
- Platelet-Derived miR-126-3p Directly Targets AKT2 and Exerts Anti-Tumor Effects in Breast Cancer Cells: Further Insights in Platelet-Cancer Interplay.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Besides their vital role in hemostasis and thrombosis, platelets are also recognized to be involved in cancer, where they play an unexpected central role: They actively influence cancer cell behavior, but, on the other hand, platelet physiology and phenotype are impacted by tumor cells. The existence of this platelet-cancer loop is supported by a large number of experimental and human studies reporting an association between alterations in platelet number and functions and cancer, often in a way dependent on patient, cancer type and treatment. Herein, we shall report on an update on platelet-cancer relationships, with a particular emphasis on how platelets might exert either a protective or a deleterious action in all steps of cancer progression. To this end, we will describe the impact of (i) platelet count, (ii) bioactive molecules secreted upon platelet activation, and (iii) microvesicle-derived miRNAs on cancer behavior. Potential explanations of conflicting results are also reported: Both intrinsic (heterogeneity in platelet-derived bioactive molecules with either inhibitory or stimulatory properties; features of cancer cell types, such as aggressiveness and/or tumour stage) and extrinsic (heterogeneous characteristics of cancer patients, study design and sample preparation) factors, together with other confounding elements, contribute to "the Janus face" of platelets in cancer. Given the difficulty to establish the univocal role of platelets in a tumor, a better understanding of their exact contribution is warranted, in order to identify an efficient therapeutic strategy for cancer management, as well as for better prevention, screening and risk assessment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.